Rare Kidney Diseases Market Growth Trajectory Through 2024-2033

Spread the love

The Rare Kidney Diseases Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Rare Kidney Diseases Market:

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

According to The Business Research Company’s Rare Kidney Diseases Global Market Report 2024, The rare kidney diseases market size has grown rapidly in recent years. It will grow from $2.52 billion in 2023 to $2.8 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to increased disease recognition, orphan drug designations, patient advocacy and awareness, global collaborations in research..

The rare kidney diseases market size is expected to see strong growth in the next few years. It will grow to $4.07 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to emergence of gene therapies, increasing investment in rare disease research, growing collaboration between stakeholders, global initiatives for rare diseases.. Major trends in the forecast period include patient-centric approach, real-world evidence and data analytics, regulatory developments, telemedicine and remote monitoring, global health initiatives..

Government initiatives and funding for kidney disorders are expected to propel the growth of the rare kidney disease market going forward. A government initiative and funding are a type of government financial support given to selected entities with ideas or projects that contribute to and improve public services and the economy. The government provides aid in kidney disorders to enhance disease surveillance and improve the quality of life for persons with various kidney diseases by using a comprehensive public health strategy that includes other public health agencies and national organizations. For instance, in July 2022, The United States House Committee on Appropriations, a US-based committee of the House of Representatives, initiated various investment programs to promote kidney health. It includes $8.5 million in funding for the Centers for Disease Control and Prevention’s (CDC) chronic kidney disease program to accelerate activities to promote regular kidney disease awareness, diagnosis, and treatment. Further, a living donation investment of $1 million was made to boost the national living donor assistance center, bringing the total to $8 million in ongoing investment in innovation and research. Therefore, government initiatives and funding for kidney disorders are driving the growth of the rare kidney disease market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=11908&type=smp

The rare kidney diseases market covered in this report is segmented –

1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications

2) By Type of Molecule: Small Molecules, Biologics

3) By Route of administration: Oral, Intravenous, Subcutaneous, Other Routes of Administration

Product innovation is a key trend gaining popularity in the rare kidney disease market. Major market players are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in September 2022, STADA Arzneimittel AG, a Germany-based company operating in generics, specialty pharma, and non-prescription consumer healthcare products, introduced Kinpeygo (budesonide), the first medicine authorized in the EU for treating rare kidney disease for treating a rare kidney disease immunoglobulin A nephropathy (IgAN). The modified-release budesonide capsules are the first and only approved treatment in the EU for primary IgAN, a rare, progressive autoimmune kidney disease with a high unmet need, with more than 25%-30% of patients eventually developing terminal kidney insufficiency requiring dialysis or kidney transplantation.

The rare kidney diseases market report table of contents includes: